News headlines about Quidel Corporation (NASDAQ:QDEL) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quidel Corporation earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.2184033565443 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Quidel Corporation (QDEL) opened at $38.00 on Friday. The company has a quick ratio of 5.68, a current ratio of 6.28 and a debt-to-equity ratio of 0.70. Quidel Corporation has a twelve month low of $18.25 and a twelve month high of $45.55.
Quidel Corporation (NASDAQ:QDEL) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.21). The business had revenue of $50.89 million for the quarter, compared to the consensus estimate of $50.47 million. Quidel Corporation had a negative net margin of 2.33% and a negative return on equity of 2.36%. Quidel Corporation’s revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.10 earnings per share. equities analysts anticipate that Quidel Corporation will post 0.6 earnings per share for the current year.
A number of equities analysts recently commented on the company. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $50.00 target price on shares of Quidel Corporation in a report on Friday, November 3rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $48.00 target price on shares of Quidel Corporation in a report on Wednesday, October 25th. Barclays PLC reaffirmed a “buy” rating and issued a $45.00 target price (up from $39.00) on shares of Quidel Corporation in a report on Tuesday, September 19th. TheStreet cut Quidel Corporation from a “b-” rating to a “c” rating in a report on Wednesday, July 26th. Finally, Zacks Investment Research raised Quidel Corporation from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a report on Friday, October 13th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Quidel Corporation currently has a consensus rating of “Buy” and a consensus price target of $48.80.
In other news, SVP Werner Kroll sold 7,565 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $39.50, for a total transaction of $298,817.50. Following the completion of the transaction, the senior vice president now owns 10,261 shares in the company, valued at $405,309.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $42.91, for a total value of $1,544,760.00. Following the transaction, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $12,722,514.63. The disclosure for this sale can be found here. Over the last three months, insiders have sold 135,530 shares of company stock worth $5,414,976. Insiders own 22.00% of the company’s stock.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.